The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Edward Abraham

Division of Pulmonary Sciences and Critical Care Medicine

University of Colorado Health Sciences Center

Denver 80262



Name/email consistency: high



  • Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver 80262, USA. 1998 - 2005


  1. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. Abraham, E., Laterre, P.F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B.L., François, B., Guy, J.S., Brückmann, M., Rea-Neto, A., Rossaint, R., Perrotin, D., Sablotzki, A., Arkins, N., Utterback, B.G., Macias, W.L. N. Engl. J. Med. (2005) [Pubmed]
  2. Effects of recombinant human activated protein C in human models of endotoxin administration. Abraham, E. Proc. Am. Thorac. Soc (2005) [Pubmed]
  3. Alterations in cell signaling in sepsis. Abraham, E. Clin. Infect. Dis. (2005) [Pubmed]
  4. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. Abraham, E., Gyetko, M.R., Kuhn, K., Arcaroli, J., Strassheim, D., Park, J.S., Shetty, S., Idell, S. J. Immunol. (2003) [Pubmed]
  5. Nuclear factor-kappaB and its role in sepsis-associated organ failure. Abraham, E. J. Infect. Dis. (2003) [Pubmed]
  6. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., Beale, R., Svoboda, P., Laterre, P.F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettilä, V., Artigas, A., Percell, S.R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J.C., Creasey, A.A. JAMA (2003) [Pubmed]
  7. Computational design of variant TNF molecules: a novel methodology for inhibition of proinflammatory cascades. Abraham, E. Sci. STKE (2003) [Pubmed]
  8. The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?. Abraham, E. Crit. Care (2002) [Pubmed]
  9. Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5'-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. Abraham, E., Arcaroli, J., Shenkar, R. J. Immunol. (2001) [Pubmed]
  10. HMG-1 as a mediator of acute lung inflammation. Abraham, E., Arcaroli, J., Carmody, A., Wang, H., Tracey, K.J. J. Immunol. (2000) [Pubmed]
  11. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Abraham, E., Carmody, A., Shenkar, R., Arcaroli, J. Am. J. Physiol. Lung Cell Mol. Physiol. (2000) [Pubmed]
  12. Effects of propofol containing EDTA on mineral metabolism in medical ICU patients with pulmonary dysfunction. Abraham, E., Papadakos, P.J., Tharratt, R.S., Hall, J.B., Williams, G.J. Intensive. Care. Med (2000) [Pubmed]
  13. Sepsis and mediator-directed therapy: rethinking the target populations. Mediator-directed therapy in sepsis: rethinking the target populations. Toronto, Canada, 31 October-1 November 1998. Abraham, E., Marshall, J.C. Mol. Med. Today (1999) [Pubmed]
  14. Why immunomodulatory therapies have not worked in sepsis. Abraham, E. Intensive. Care. Med (1999) [Pubmed]
  15. Cytokine modifiers: pipe dream or reality?. Abraham, E. Chest (1998) [Pubmed]
WikiGenes - Universities